RecruitingPhase 1NCT07591155
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of BL-ARC002 for Injection in Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Enrollment
22 participants
Start Date
May 13, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-ARC002 for injection in patients with locally advanced or metastatic solid tumors.
Eligibility
Min Age: 18 Years
Inclusion Criteria14
- Voluntarily sign the informed consent form and comply with the protocol requirements;
- No gender restrictions;
- Age: ≥18 and ≤75 years (Phase Ia); ≥18 years (Phase Ib);
- Expected survival time ≥3 months;
- Histopathologically and/or cytologically confirmed locally advanced or metastatic solid tumors that have failed standard treatment;
- Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic lesions within the past 2 years;
- Must have at least one measurable lesion as defined by RECIST v1.1;
- Eastern Cooperative Oncology Group performance status of 0 or 1;
- Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
- No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;
- Organ function levels must meet the required criteria;
- Coagulation function: International normalized ratio ≤1.5 and activated partial thromboplastin time ≤1.5 × upper limit of normal;
- Urine protein ≤2+ or ≤1000 mg/24 hours;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with serum pregnancy test being negative, and they must not be breastfeeding; all enrolled patients (regardless of sex) must practice adequate barrier contraception throughout the entire treatment period and for 6 months after treatment completion.
Exclusion Criteria17
- Use of chemotherapy, biotherapy, immunotherapy, etc., within 4 weeks or 5 half-lives prior to the first dose;
- History of serious heart disease;
- QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block;
- Active autoimmune diseases and inflammatory diseases;
- Diagnosis of another malignancy within 5 years prior to the first dose;
- Hypertension inadequately controlled by two antihypertensive medications;
- History of ILD requiring steroid therapy, current ILD, or ≥ Grade 2 radiation pneumonitis;
- Active symptoms of central nervous system metastasis;
- History of allergy to recombinant humanized or human-mouse chimeric antibodies, or allergy to any excipient component of BL-ARC002;
- Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Cumulative anthracycline dose > 360 mg/m² from prior (neo)adjuvant anthracycline-based therapy;
- Positive for human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
- Active infection requiring systemic therapy;
- Participation in another clinical trial within 4 weeks prior to the first dose;
- Pregnancy or breastfeeding;
- Study participants with claustrophobia or any condition preventing them from lying still to complete examinations;
- Other conditions deemed by the investigator to make the participant unsuitable for this clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBL-ARC002
Administration by intravenous infusion for a cycle of 6 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07591155
Related Trials
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
NCT073748485 locations
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
NCT075384791 location
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT0718168114 locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873781 locations
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT045704235 locations